138 related articles for article (PubMed ID: 34024275)
1. Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective.
Ni W; Liu J; Jiang Y; Wu J
BMC Ophthalmol; 2021 May; 21(1):229. PubMed ID: 34024275
[TBL] [Abstract][Full Text] [Related]
2. A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO).
Taylor M; Serbetci E; Ferreira A; Gairy K; Lewis L; Blouin J; Mitchell P
J Med Econ; 2014 Jun; 17(6):423-34. PubMed ID: 24673384
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
Adedokun L; Burke C
Adv Ther; 2016 Jan; 33(1):116-28. PubMed ID: 26747252
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
Campochiaro PA; Sophie R; Pearlman J; Brown DM; Boyer DS; Heier JS; Marcus DM; Feiner L; Patel A;
Ophthalmology; 2014 Jan; 121(1):209-219. PubMed ID: 24112944
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
Haig J; Barbeau M; Ferreira A
J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.
Nghiem-Buffet S; Baillif S; Regnier S; Skelly A; Yu N; Sodi A
Eye (Lond); 2017 Apr; 31(4):551-559. PubMed ID: 27911446
[TBL] [Abstract][Full Text] [Related]
8. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.
Bhisitkul RB; Campochiaro PA; Shapiro H; Rubio RG
Ophthalmology; 2013 May; 120(5):1057-63. PubMed ID: 23415775
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
[TBL] [Abstract][Full Text] [Related]
10. [Six Months Outcome in Patients with Macular Edema Due to Retinal Vein Occlusion Treated with Ranibizumab].
Sakanishi Y; Ouchi A; Ito R; Ebihara N
Nippon Ganka Gakkai Zasshi; 2016 Jan; 120(1):28-34. PubMed ID: 26950966
[TBL] [Abstract][Full Text] [Related]
11. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
12. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
13. [Two-Year Follow-up Results of Patients with Macular Oedema Due to Retinal Vein Occlusion Treated with Ranibizumab].
Hladíková Z; Klofáčová E; Kalvodová B
Cesk Slov Oftalmol; 2017; 73(2):43-51. PubMed ID: 28931295
[TBL] [Abstract][Full Text] [Related]
14. Retinal Vein Occlusion.
Sawada O; Ohji M
Dev Ophthalmol; 2016; 55():147-53. PubMed ID: 26501219
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion.
Thom HH; Capkun G; Nixon RM; Ferreira A
BMC Med Res Methodol; 2014 Dec; 14():140. PubMed ID: 25533265
[TBL] [Abstract][Full Text] [Related]
17. Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO.
Tang F; Xu F; Zhong H; Zhao X; Lv M; Yang K; Shen C; Huang H; Lv J; Zeng S; Li M; Chen Q
BMC Ophthalmol; 2019 Jun; 19(1):133. PubMed ID: 31226968
[TBL] [Abstract][Full Text] [Related]
18. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
[TBL] [Abstract][Full Text] [Related]
19. Neuroretinal atrophy following resolution of macular oedema in retinal vein occlusion.
Podkowinski D; Philip AM; Vogl WD; Gamper J; Bogunovic H; Gerendas BS; Haj Najeeb B; Waldstein SM; Schmidt-Erfurth U
Br J Ophthalmol; 2019 Jan; 103(1):36-42. PubMed ID: 29511062
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal.
Vaz-Pereira S; Marques IP; Matias J; Mira F; Ribeiro L; Flores R
Eur J Ophthalmol; 2017 Nov; 27(6):756-761. PubMed ID: 28315518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
